Introduction
============

Chronic kidney disease (CKD) patients are affected by considerable cardiovascular morbidity and mortality. Cardiovascular complications are the main cause of death among patients on dialysis ([@b46]; [@b12]) and cardiovascular mortality rates are approximately 10--20 times greater than those observed in the general population ([@b18]). The burden of cardiovascular disease is huge also during the conservative phase of CKD: the number of CKD patients progressing towards the need for renal replacement treatment is indeed much lower than the number of those dying, mainly due to cardiovascular disease itself, before reaching the point of end-stage renal disease (ESRD) ([@b32]; [@b15]). In this context, anemia has gained increasing attention, based on its well documented role as a specifically CKD-related cardiovascular risk factor. Anemia is a frequent complication of patients with CKD and is mainly characterized by a reduced ability of the damaged kidney to produce erythropoietin (EPO), the hormone involved in proliferation and maturation of red blood cells in the bone marrow. Hb levels can start to decrease even at an early stage of CKD ([@b37]; [@b4]). It has been found that among patients with a creatinine clearance of more than 50 mL/min (early kidney disease), 25% have already developed anemia (defined as Hb \<13 mg/dL), and the prevalence of anemia increases dramatically as creatinine clearance further decreases ([@b37]). Anemia is often more severe and occurs at an earlier stage in patients with diabetic nephropathy in comparison with patients with CKD of other causes ([@b66]).

Association of renal anemia with cardiovascular morbidity and mortality
=======================================================================

Several reports have shown an association between of anemia and the development of cardiovascular complications in patients with CKD ([@b24]; [@b54]; [@b38]). It is thought that these associations are mainly due to the impact of chronic anemia on cardiac function, by means of vasodilation, cardiac dilation, and increased cardiac output, finally leading to left ventricular dilation and compensatory hypertrophy ([@b3]). The association between anemia and cardiovascular disease can also be explained by the reduction in oxygen delivery throughout the body, whereas it has been suggested that anemia, congestive heart failure, and CKD are all interrelated, each causing the other to worsen, resulting in a vicious cycle of disease progression ([@b63]). Complications that have been most consistently associated with anemia are indeed left ventricular hypertrophy, congestive heart failure, and ischemic heart disease ([@b16]; [@b38]).

Anemia-related cardiovascular abnormalities play a significant role in mortality in patients with CKD, and a number of observational studies have described a clear relationship between anemia and mortality in CKD patients. In studies performed on large populations of prevalent hemodialysis patients in the US, both total mortality rate and cardiovascular-related mortality rate were shown to increase along with the decrease in hematocrit ([@b50]; [@b49]; [@b12]). These registry studies were, however, much limited by considering only a few number of potentially confounding covariates. This is not the case for the DOPPS study, which took into account a large number of case-mix characteristics and found significantly lower relative risks of mortality and all-cause hospitalization for every 1 g/dL higher hemoglobin concentration, both in a European ([@b43]) and US ([@b58]) large sample population of hemodialysis patients. More recently, a systematic review of published observational studies investigating anemia and mortality in dialysis patients confirmed a consistent trend towards increased mortality with decreasing Hb levels ([@b67]). Although less consistent, recent observations indicate a clear association between anemia and increased mortality also in CKD patients who are not yet on dialysis ([@b35]; [@b39]). It should, however, be borne in mind that most observational studies have so far considered only the point values of hemoglobin or hematocrit, which may be misleading due to the fact that many patients do not have stable Hb levels over time: that is the reason why some observational studies of patients in the conservative phase of CKD have used time-averaged rather than single hemoglobin values when analyzing their impact on patients' survival ([@b12]; [@b57]).

The presence of anemia during the early stages of CKD may also fasten the progression of kidney damage. Reduced oxygen delivery to the kidney caused by anemia may indeed lead to a progressive destruction of tubules, interstitial fibrosis, and increased oxidative stress, all factors which are expected to favor the progression of the disease ([@b61]). Clinical studies support the presence of a positive association between higher hemoglobin levels and a decrease in the rate of loss of renal function ([@b36]; [@b27]), and ongoing trials are investigating the possible benefits of correcting hemoglobin levels on the progression of CKD.

Clinical benefits of correcting renal anemia
============================================

The availability of recombinant human erythropoietin (rHuEPO) has greatly changed the management of anemia in patients with CKD, allowing hemoglobin levels to be effectively moved towards higher values. The gene encoding for EPO was cloned in 1985 ([@b42]) and rHuEPO has been used in the treatment of renal anemia since 1986 ([@b69]; [@b14]). Since then, a number of clinical trials have documented that the administration of rHuEPO maintains adequate hemoglobin levels and avoids transfusion dependency in CKD patients. Starting from the clear association observed between lower hemoglobin levels and increased mortality in CKD patients, the availability of an effective therapeutic instrument to treat renal anemia soon raised the question as to whether correcting anemia may be able to improve patient outcome. Several intervention studies have been performed to test this hypothesis. Many of these studies were also aimed at verifying, through randomized allocation of the patients to different target hemoglobin levels, whether complete rather than partial correction of renal anemia through rHuEPO administration would lead to the best results in terms of survival or surrogate endpoints (left ventricular mass, quality of life).

Patients with CKD not receiving dialysis are less likely to have already established cardiovascular disease, as the prevalence of left ventricular hypertrophy and heart disease progressively increases as renal function declines ([@b41]). Therefore, it has been hypothesized that they may benefit more from anemia correction. Preliminary data from mainly small, uncontrolled studies indicated that anemia correction was able to lead to partial regression of left ventricular hypertrophy ([@b56]; [@b25]; [@b19]), although such an effect was not confirmed in more recent studies ([@b59]). However, it must be pointed out that the randomized controlled trial by [@b59] suffered from the relative closeness of the achieved hemoglobin values between the two randomization groups, whereas [@b40] observed an inverse relationship between the decrease in hemoglobin levels and left ventricular mass index among the patients whose hemoglobin decreased by ≥1.0 g/dL during follow-up, regardless of the trial arm.

[@b7] were the first who tested the effect of hemoglobin normalization, as compared with only partial anemia correction, in patients on dialysis. The study, which considered hard outcomes such as mortality and cardiac events, was actually halted after 29 months because the trends in mortality/acute myocardial infarction in the two randomization arms were such that it was unlikely that any benefit would be obtained from complete anemia correction. However, the study population consisted of hemodialysis patients aged more than 65 years with clinical evidence of congestive heart failure or ischemic heart disease, who were suggested to be affected by too many co-morbidities to benefit from anemia normalization, and it is also possible that the co-existence of reduced cardiac output and vascular grafts in the majority (almost 70%) of the study population may have increased the likelihood of adverse events secondary to complete anemia correction, including graft thrombosis. Furthermore, a secondary analysis did reveal an inverse relationship between hematocrit values and mortality rates in both groups, with the patients who actually achieved a level of 42% showing the best survival rate, although this finding might have been due to survivor selection. Other studies performed in less compromised dialysis patients did not find a significant effect of complete anemia correction on survival, but such studies were not specifically designed to test mortality [@b21]; [@b55]). Also surrogate endpoints, such as left ventricular mass, were not shown to be positively affected by the achievement of higher hemoglobin levels through rHuEPO administration in dialysis patients [@b17]; [@b55]), with the exception of only quality of life, which seems to be positively influenced by complete anemia correction [@b51]; [@b21]; [@b55]).

Fewer data exist on the effects of complete anemia correction on clinical outcome in CKD patients not receiving dialysis. The clinical trial by [@b60] did not find any difference in the risk of cardiovascular adverse events between patients randomized to different hemoglobin targets, but the study was primarily aimed at testing the effect of treatment on the rate of progression of CKD rather than on cardiovascular prognosis. Further important information as to this point will be provided by on-going or just ended clinical trials, such as the Cardiovascular Reduction Early Anemia Treatment Epoetin beta (CREATE) study and the Anemia CORrection in Diabetes (ACORD) trial, but the preliminary results of these studies do not seem to show any cardiovascular advantage in favor of complete anemia correction in CKD patients not yet on dialysis.

Altogether, the results of the available studies published so far indicate that partial correction of renal anemia by means of rHuEPO administration is accompanied by significant improvements in cardiac structure and function, but no further major effect on survival and left ventricular mass seems to be achieved by normalizing hemoglobin levels in patients with CKD. However, caution is warranted in interpreting these results, as in most cases they were obtained from heterogeneous studies that were not primarily designed to analyze mortality and were heavily conditioned by the relative closeness of the hemoglobin values achieved during follow-up between the groups of patients randomized to different levels of anemia correction.

Epoetin beta and renal anemia
=============================

Clinical pharmacology
---------------------

Nowadays, there are three erythropoiesis-stimulating agents available on the market for the treatment of renal anemia: epoetin alfa, epoetin beta, and darbepoetin alfa. Epoetin alfa and epoetin beta are both synthesized in Chinese hamster ovary cells and share the same amino acid sequence as endogenous EPO, but differences in the manufacturing process between the two glycoproteins reflect the differences in their carbohydrate moieties [@b65]). On the contrary, darbepoetin alfa is biochemically different from endogenous EPO, due to an additional two glycosylation chains N-linked to the protein backbone of the molecule. Differences in the carbohydrate moieties of the rHuEPOs determine differences in the pharmacokinetic and pharmacodynamic properties between these agents.

The differences in pharmacokinetic and pharmacodynamic properties of epoetin beta and epoetin alfa have been confirmed in a randomized crossover study on healthy volunteers, in which the terminal elimination half-life of intravenous epoetin beta was found to be 20% longer than that observed with intravenous epoetin alfa; the half-life for epoetin beta was also longer with the subcutaneous route, although the difference did not reach statistical significance (serum concentration after subcutaneous administration appears to be higher for epoetin beta than for epoetin alfa from 48 to 66 hours after dosing, and this reflects delayed drug absorption with epoetin beta compared with epoetin alfa; in addition, epoetin beta seems to induce a greater absolute reticulocyte response than epoetin alfa after subcutaneous administration). These differences are most probably explained by the differences in the types and relative proportions of the carbohydrate side chains on the glycoprotein molecules present in the two preparations.

Pharmacokinetic and pharmacodynamic responses to epoetin beta differ greatly according to the route of administration. Although peak serum concentration is more than 10 times greater after intravenous than subcutaneous administration, the terminal elimination half-life for epoetin beta administered via subcutaneous injection is almost three-fold that of the same dose given intravenously [@b23]), likely due to the delayed absorption following subcutaneous administration. Interestingly, the absolute reticulocyte response is greater when epoetin beta is administered subcutaneously rather than intravenously [@b23]), suggesting that the response to epoetin is not related to its peak plasma concentration but rather to its maintenance above a critical threshold concentration. The prolonged half-life following subcutaneous administration of epoetin beta suggested the possibility of increasing the interval between injections when using this route of administration, as confirmed by rHuEPO levels remaining within the target range for most of the period between injections even with once-weekly subcutaneous dosing [@b8]). In addition, dose requirements to maintain target hemoglobin levels are significantly lower when epoetin beta is administered subcutaneously compared with intravenously [@b8]; [@b29]). For this reason, current treatment guidelines (Locatelli et al 2004a) recommend the subcutaneous route of administration of epoetin beta in order to minimize treatment costs.

Efficacy
--------

Although the subcutaneous route of administration is currently recommended for epoetin beta, due to pharmacological and economic considerations, it can also be given intravenously, if necessary. The efficacy of intravenous epoetin beta has actually been established in several studies in patients with CKD, either pre-dialysis or on hemodialysis (Kaupe et al 1990; [@b1]; [@b5]; [@b28]; [@b64]; [@b10]).

Nonetheless, the sustained duration of action described in pharmacokinetic studies supports the use of subcutaneous epoetin beta, administered once weekly, at least in the maintenance phase of renal anemia treatment. In fact, although traditionally rHuEPO was administered three times weekly, studies evaluating less frequent administration regimens have demonstrated that once-weekly subcutaneous administration of epoetin beta during the maintenance phase of therapy has the same efficacy in maintaining Hb levels as the three-times-weekly regimen. In particular, two large-scale, randomized, controlled studies [@b68]; [@b45]) showed that stable Hb levels could be maintained with once-weekly epoetin beta treatment without an increase in dose compared with administration two or three times weekly. [@b68] conducted an open label, randomized, controlled, parallel-group study designed to detect no difference in efficacy between once-weekly and two- or three-times-weekly subcutaneous epoetin beta treatment in 158 patients on hemodialysis. Patients with Hb levels maintained between 10 and 12.5 g/dL during an 8-week pre-treatment period with subcutaneous epoetin beta two or three times weekly were randomized either to receive once weekly subcutaneous epoetin beta treatment or to remain on their original regimen for 24 weeks. No significant differences were observed in Hb levels and in weekly epoetin beta dose between the treatment regimens. The study by [@b45] was designed to demonstrate therapeutic and statistical equivalence between once-weekly and three-times-weekly subcutaneous epoetin beta treatment in stable patients on hemodialysis. This was an open-label, randomized, parallel-group study conducted over a 24-week period: 173 patients on hemodialysis were randomized to treatment with once- or three-times-weekly epoetin beta. Mean hematocrit levels remained stable throughout the study and the mean weekly epoetin beta dose was not different in the two treatment groups.

Several small-scale studies have investigated the use of once-weekly subcutaneous epoetin also in patients on peritoneal dialysis [@b48]; [@b62]; [@b53]; [@b20]), suggesting that a maintenance dose of subcutaneous epoetin is effective when given once weekly in these patients. For example, a prospective, randomized study compared the dosage requirements of subcutaneous epoetin beta administered either once weekly or three times weekly in 39 patients on peritoneal dialysis previously stabilized on epoetin beta three times weekly [@b20]). At the endpoint there was no difference in hemoglobin levels between treatment regimens, and over the 3-month study period the average dose of epoetin beta was slightly lower for patients receiving once-weekly compared with three-times-weekly treatment. More recently, another study investigated whether epoetin beta administered once weekly was effective at maintaining hemoglobin levels in patients on peritoneal dialysis previously stabilized on epoetin two or three times weekly and whether once every two weeks administration was effective in patients previously stabilized on a once-weekly regimen [@b22]). In both cases, over the 6-month study period, the patients were able to maintain hemoglobin levels within the target range without a significant increase in overall weekly dose compared with their respective previous regimen.

As well as being effective in patients on dialysis, subcutaneous epoetin beta is effective in correcting renal anemia also in patients with CKD who do not require renal replacement therapy [@b34]). An open-label, multicenter study including 84 pre-dialysis patients suggested that once-weekly subcutaneous epoetin beta is as effective as more frequent administration in maintaining hemoglobin levels in CKD patients in the conservative phase [@b2]).

Safety and tolerability
-----------------------

More than a decade of experience with epoetin beta has demonstrated its favorable safety and tolerability profile in patients with CKD. During its clinical trial program, no long-term trend or distinct pattern in adverse events was identified (F. Hoffmann-La Roche, data on file). As with other erythropoiesis-stimulating agents (ESA), the most common adverse event is hypertension. A number of pathophysiological mechanisms have been postulated to explain the rise in blood pressure values observed after ESA administration. The increase in blood viscosity secondary to anemia correction appears as the most obvious one. This is particularly true when anemia correction is achieved too rapidly or higher hemoglobin targets are reached. However, often blood pressure changes are not clearly related to achieved hemoglobin levels. Enhanced vascular reactivity and vasoconstrictor responses have been thus suggested to play a role. Given that ESA-induced hypertension seems to be dose-related, it is possible that switching patients from intravenous to subcutaneous epoetin therapy, by allowing lower doses, may reduce the incidence of adverse events, above all hypertension. This is suggested by the results of a study on hypertensive hemodialysis patients under intravenous epoetin therapy, whose pre-dialysis blood pressure levels significantly decreased after switching to subcutaneous administration, so that within 6 months nearly half of them were no longer considered hypertensive [@b52]). A larger study of 406 patients receiving maintenance intravenous or subcutaneous epoetin treatment who were switched to subcutaneous epoetin beta showed epoetin beta to be well tolerated and effective, with adverse events occurring at a very low rate during the study [@b33]). Finally, different studies reported that once-weekly subcutaneous epoetin beta is as well tolerated as two- or three-times-weekly regimens [@b68]; [@b45]). It must also be considered that the reduced dosage requirements when epoetin is administered subcutaneously compared with intravenously may allow substantial cost savings, without compromising effectiveness or safety of therapy [@b29]; [@b9]; [@b26]).

Antibody-mediated pure red cell aplasia (PRCA) is a rare complication following therapy with ESA. Between 1998 and 2002, an upsurge of PRCA cases have been described, but this was mainly related to treatment with epoetin alfa [@b11]; [@b6]). Reports of PRCA with epoetin beta have been sporadic and limited [@b44]).

Conclusions
===========

Anemia is a frequent and early complication of CKD and is associated with adverse cardiovascular outcomes and poor patient survival. Renal anemia can be effectively managed by the administration of rHuEPO, which is able to increase hemoglobin levels and has been associated with significant improvements in the cardiovascular status of patients with CKD. Epoetin beta represents one of the three erythropoiesis-stimulating agents available on the market for the treatment of renal anemia. The increased effectiveness and the longer half-life shown by epoetin beta when administered subcutaneously, as compared with intravenously, make the subcutaneous route of administration the one recommended by current best practice guidelines, allowing target hemoglobin levels to be maintained at a lower epoetin dose and lower frequency of administration.

The ability to administer epoetin beta once weekly is associated with several additional benefits. Reducing administration frequency from three times weekly to once weekly is likely to improve patients' acceptance of epoetin treatment, potentially encouraging self-administration and improving compliance. The once-weekly schedule contributes also to the reduction of treatment costs and nursing time required for optimal anemia management.

In conclusion, the proven efficacy and safety profile of epoetin beta, combined with the increased convenience of less frequent dosing, make epoetin beta a safe and effective treatment option that can help more patients to reach their therapeutic targets in the management of renal anemia.
